echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Science subjournal: tumor specific antibody targeted inhibition of Ras mutant tumors

    Science subjournal: tumor specific antibody targeted inhibition of Ras mutant tumors

    • Last Update: 2020-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    February 20, 2020 / Biogen / -- oncogenic Ras mutant (rasmut) protein is unable to be contacted and targeted by conventional antibodies due to its position in the cell, so it is impossible to target this mutation and treat cancer through conventional antibody program

    Picture source; Science advanced recently came from South Korea Asian University, chengjunguan University and orum therapeutics In cooperation with researchers from Inc, an IgG antibody targeting pan RAS, inras37, was reported

    The antibody can be specifically internalized into the cytoplasm of tumor cells and directly act on various rasmut subtypes activated in cells, blocking their interaction with effector proteins, thus inhibiting their downstream signal transduction

    Injecting inras37 into mice with small rasmut xenograft tumor by systemic administration can produce strong antitumor activity, but this antibody has little effect on the downstream rasmut tumor with simultaneous PI3K mutation, which can be overcome by combining PI3K inhibitor

    The researchers found that the Yap1 protein in rasmut dependent colorectal tumors can be up-regulated and lead to drug resistance under the induction of inras37, so inras37 combined with Yap1 inhibitor has synergistic antitumor effect in vivo and in vitro

    All in all, this study provides a promising antibody targeting Ras mutant tumor and corresponding treatment strategy, breaking the phenomenon that the antibody can not target this mutation

    Reference materials: Yong Sung Kim et al

    Direct targeting of oncogenic Ras mutants with a tumor specific cytosol pentrating antibility investments Ras mutant driven tumor growth

    Science advances 15 Jan 2020: Vol

    6, No

    3, eaay2174 doi: 10.1126/sciadv.aay2174
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.